Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5333828 | 0.95 | P2RY12 (0.72) | P2RY12TERT | |
| SCHEMBL5338189 | 0.95 | TERT (0.69) | P2RY12TERT | |
| SCHEMBL31312543 | 0.85 | TERT (0.76) | P2RY12TERT | |
| SCHEMBL5341217 | 0.81 | TERT (0.98) | P2RY12TERT | |
| SCHEMBL10068096 | 0.78 | P2RY12 (0.90) | P2RY12TERT | |
| SCHEMBL5332048 | 0.77 | TERT (1.00) | P2RY12TERT | |
| SCHEMBL5337682 | 0.77 | TERT (1.00) | P2RY12TERT | |
| SCHEMBL7931748 | 0.76 | P2RY12 (0.82) | P2RY12TERT | |
| SCHEMBL5337185 | 0.75 | TERT (1.00) | P2RY12TERT | |
| SCHEMBL5339762 | 0.74 | TERT (1.00) | TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7300930-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-27 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-7160896-B2 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-01-09 | — | — | US | disclosed |
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111389-A1 | Therapeutic acridone and acridine compounds | TERT, ACIN1, NAT1 | P2RY12 3821/4885TERT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.